4-吡啶-3-基-苯甲酸 | 4385-75-5

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-吡啶-3-基-苯甲酸
• 中文别名: 4-吡啶-3-基苯甲酸
• 英文名称: 4-(pyridine-3-yl)benzoic acid
• 英文别名: 4-[pyridin-3-yl]-benzoic acid；4-(3-pyridyl)benzoic acid；4-Pyridin-3-yl-benzoic acid；4-pyridin-3-ylbenzoic acid
• CAS: 4385-75-5
• 化学式: C₁₂H₉NO₂
• 分子量: 199.209
• InChiKey: GYUKEVKPDRXPAB-UHFFFAOYSA-N

物化性质

• 熔点：
  271-274
• 沸点：
  398.8±25.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将药品存放在避光、通风干燥的地方，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(3-Pyridyl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(3-Pyridyl)benzoic acid
CAS number: 4385-75-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H9NO2
Molecular weight: 199.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-吡啶-3-基-苯甲酸 以 间氯过氧苯甲酸 为溶剂， 以86%的产率得到4-(1-oxido-3-pyridinyl)benzoic acid
  参考文献：
  名称：

  Pharmaceutically active pyrrolidine derivatives

  摘要：

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。

  公开号：

  US20030212012A1
• 作为产物：
  描述：

  对溴甲苯 在 potassium permanganate 、 四(三苯基膦)钯 、 四丁基溴化铵 、 碘 、 caesium carbonate 、 magnesium 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 54.0h， 生成 4-吡啶-3-基-苯甲酸
  参考文献：
  名称：

  Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents

  摘要：

  As a continuation to our previous research, twenty-eight aromatic-heterocyclic biphenyls were designed and synthesized as novel Bcr-Abl inhibitors. The title compounds were investigated for their anti-proliferative activities against wild K562 cells and Imatinib-resistant K562 cells (K562R). The results indicated that most of them exhibited potent Bcr-Abl inhibition and moderate antiproliferative potency against K562 cells. Furthermore, three compounds 3, 7 and 21 displayed moderate antiproliferative activities against K562R cells. Molecular docking indicated that 3 bound more tightly with Bcr-Abl(T315I) compared to Bcr-Abl(WT). The higher affinity was consistent with its relatively promising K562R cell growth inhibition. These aromatic-heterocyclic biphenyls could be considered as novel lead compound for optimized as Bcr-Abl(T315I) inhibitors. They provide a good starting point for the further development of novel anti-leukemia agents capable of dealing with clinical acquired resistance against Imatinib. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.07.015
• 作为试剂：
  描述：

  4-羧基苯硼酸 、 3-溴吡啶 、 potassium carbonate 在 双三苯基磷二氯化钯 二氯甲烷 、 水 、 4-吡啶-3-基-苯甲酸 作用下， 以 乙腈 、 水 为溶剂， 反应 24.0h， 以to obtain 1.7 g of white solid of 4-(pyridin-3-yl)benzoic acid的产率得到4-吡啶-3-基-苯甲酸
  参考文献：
  名称：

  BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

  摘要：

  一种具有以下式子（I）或式子（II）结构的化合物：其中变量Y，R1，R2，R3和R4如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性抑制剂。本文还描述了包括至少一种本文所述化合物的制药组合物，以及使用本文所述的化合物或制药组合物来治疗通过抑制PARP活性改善的疾病，障碍和病况。

  公开号：

  US20090197863A1

文献信息

• Design, synthesis and stepwise optimization of nitrile-based inhibitors of cathepsins B and L
  作者：Lorenzo Cianni、Fernanda Dos Reis Rocho、Vinícius Bonatto、Felipe Cardoso Prado Martins、Jerônimo Lameira、Andrei Leitão、Carlos A. Montanari、Anwar Shamim

  DOI：10.1016/j.bmc.2020.115827

  日期：2021.1

  Human cathepsin B (CatB) is an important biological target in cancer therapy. In this work, we performed a knowledge-based design approach and the synthesis of a new set of 19 peptide-like nitrile-based cathepsin inhibitors. Reported compounds were assayed against a panel of human cysteine proteases: CatB, CatL, CatK, and CatS. Three compounds (7h, 7i, and 7j) displayed nanomolar inhibition of CatB

  人组织蛋白酶 B (CatB) 是癌症治疗中的重要生物学靶点。在这项工作中，我们采用了一种基于知识的设计方法，并合成了一组新的 19 种肽样腈基组织蛋白酶抑制剂。针对一组人半胱氨酸蛋白酶对报告的化合物进行了分析：CatB、CatL、CatK 和 CatS。三种化合物（7h、7i和7j）显示出对 CatB 的纳摩尔抑制以及对 CatK 和 CatL 的选择性。的选择性通过使用的组合来实现对位联苯环在P 3，卤代苯丙氨酸P 2和Thr-O-BZ组在P 1。同样地，化合物7I和7J在所研究的酶组中显示出选择性 CatB 抑制作用。我们还描述了一个成功的例子，用生物等排置换磺酰胺 [ 7e  →  6b ]的酰胺键，我们观察到 CatB 的亲和力和选择性增加，同时降低了化合物的亲脂性 (ilogP)。我们基于知识的设计方法和各自的结构-活性关系为治疗相关组织蛋白酶的特定配体-靶标相互作用提供了见解。
• Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
  申请人：Failli A. Amedeo

  公开号：US20060287522A1

  公开（公告）日：2006-12-21

  This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

  这项发明提供了从式（1）中选择的吡咯苯并二氮杂吡咯烷吡啶羧酰胺，其作为卵泡刺激素受体拮抗剂。该发明还提供了利用式（1）和（2）化合物的药物组合物和治疗方法。
• N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
  申请人：——

  公开号：US20030092698A1

  公开（公告）日：2003-05-15

  This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

  这项发明涉及N-酰基吡咯啉-2-基烷基苯甲酰胺衍生物，用于通过将这些衍生物与含有凝血因子Xa的组合物接触来抑制凝血因子Xa的活性。本发明还涉及含有这些衍生物的组合物、它们的制备方法，以及它们的用途，例如用于抑制凝血酶的形成或用于治疗患有与生理上有害的凝血酶过量相关的疾病状态的患者。
• [EN] ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-1" PATHWAY AND METHODS OF USE THEREOF<br/>[FR] ACTIVATEURS DE LA VOIE DU GÈNE INDUCTIBLE PAR L'ACIDE RÉTINOÏQUE "RIG-1" ET LEURS PROCÉDÉS D'UTILISATION
  申请人：KINETA INC

  公开号：WO2020033782A1

  公开（公告）日：2020-02-13

  The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

  本发明涉及式(I)化合物，该化合物是RIG-I通路的激活剂。
• Structural Modifications of Salicylates: Inhibitors of Human CD81‐Receptor HCV‐E2 Interaction
  作者：Marcel Holzer、Sigrid Ziegler、Alexander Neugebauer、Bernd Kronenberger、Christian D. Klein、Rolf W. Hartmann

  DOI：10.1002/ardp.200700261

  日期：2008.8

  extracellular loop (LEL) of the CD81‐receptor (crystal structure: PDB‐ID: 1G8Q). After benzyl salicylate had been experimentally validated to be a moderate inhibitor of the CD81‐LEL–HCV‐E2 interaction, further optimization was performed and heterocyclic‐substituted benzyl salicylate derivatives were synthesized. The compounds were tested for their ability to inhibit the interaction of a fluorescence‐labeled

  本文的出发点是使用 CD81 受体（晶体结构：PDB-ID：1G8Q）的大细胞外环（LEL）的开放构象进行虚拟筛选的结果。在实验证实水杨酸苄酯是 CD81-LEL-HCV-E2 相互作用的温和抑制剂后，进行了进一步优化并合成了杂环取代的水杨酸苄酯衍生物。使用 HUH7.5 细胞测试了这些化合物抑制荧光标记抗体与 CD81-LEL 相互作用的能力。与水杨酸苄酯相比，没有化合物显示出抑制蛋白质-蛋白质相互作用的增加。